Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cascadian Therapeutics Inc (CASC)

Cascadian Therapeutics Inc (CASC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cascadian Therapeutics Inc 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121 USA

www.cascadianrx.com P: 206-801-2100

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company's product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington.

Key Statistics

Overview:

Market Capitalization, $K 507,212
Shares Outstanding, K 50,620
Annual Sales, $ 0 K
Annual Net Income, $ -56,930 K
60-Month Beta 3.80
% of Insider Shareholders 1.10%
% of Institutional Shareholders 81.38%

Growth:

1-Year Return 141.06%
3-Year Return -5.11%
5-Year Return -25.11%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -46.72%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.28 on 11/08/17
Next Earnings Date 03/08/18
Earnings Per Share ttm -0.88
EPS Growth vs. Prev Qtr 6.67%
EPS Growth vs. Prev Year 48.14%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Next Ex-Dividends Date 11/13/12
Dividend Payable Date 11/26/12
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 11/29/16

CASC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -41.50%
Return-on-Assets % -39.04%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 4.65
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar